Editorial Article
No One Is Obliged to Pay: The Real Constraint in Medication Dispensing
There is a device that costs about a dollar a day, keeps a medication record that a clinician can read, and sells into a population of 61.3 million Americans aged 65 and over. It has been on the market for the better part of two decades. Its reach is 3.20 million patient-years worldwide — less than one nineteenth of the US over-65 population on its own.
That is the fact that reorganises this market, and it is not a technology fact. Pheonix Research sizes global smart pill dispensing at USD 1,850.0 million in 2025, built on 3.20 million patient-years under managed dispensing — one person, one year, whose medication is dispensed through a managed device or a pharmacy-filled adherence pack. By 2033 the model reaches USD 4,912.0 million on 6.24 million patient-years. The number that matters is not the CAGR. It is that 3.20 million patient-years covers a small fraction of the addressable base, and the reason is that nobody is obliged to buy one.
What the household is actually asked to pay
Hero, the best-known consumer dispenser in the United States, publishes its pricing plainly: USD 39.99 a month on a prepaid annual plan, USD 44.99 on a monthly plan with a twelve-month commitment, USD 59.99 with no commitment at all. That is USD 480 to USD 720 per patient-year, plus the pills.
Now consider who pays it. The person who needs a locked dispenser is, by definition, managing several chronic conditions, frequently cognitively impaired, and often on a fixed income with a Part D premium, cost-sharing and a rising out-of-pocket cap already taken out of it. The category has priced itself at the level of a streaming subscription for a population to whom USD 60 a month is a budget decision, and it has asked that population to fund an intervention whose financial benefit accrues to somebody else.
Medicare does not close the gap. Automatic pill dispensers are not a covered benefit under Part A or Part B, and the device does not satisfy the durable medical equipment tests that would place it there. The nearest adjacent benefits do not reach it either: the Part D medication therapy management programme pays a pharmacist to conduct a comprehensive medication review, which is a valuable service and not a device; and while some Medicaid waiver programmes cover dispensers, coverage is a state-by-state patchwork rather than a benefit category.
So the market’s largest buyer is a family, its second-largest buyer is a state legislature, and its third is a capitated health plan that has to be persuaded the arithmetic works. Only one of those three can be sold to with a conventional pitch.
The asymmetry that explains everything
A patient-year of managed dispensing costs USD 480 to USD 720. An avoidable hospital admission costs an order of magnitude more. On any reasonable calculation, the intervention is worth buying — for whoever carries the risk of the readmission.
That is not the household. It is not the prescriber either, who is paid for the visit and not for the outcome. It is the entity holding a capitated or per-member budget: a PACE organisation, a Medicaid managed care plan, a long-term care operator whose per-diem absorbs the rehospitalisation, or a Medicare Advantage plan trying to move a quality score.
Where those entities exist, the market behaves completely differently. PACE programmes grew from 178 at the end of 2024 to 198 by December 2025, across 33 states and the District of Columbia, and PACE is a full-risk model: the programme provides or pays for all of a participant’s care, so an avoided admission is money it keeps. That is the single fastest-growing at-risk channel in this market, and it grew by twenty programmes in a year.
Long-term care is the other. There are 1,282 long-term care pharmacies serving 14,827 certified nursing facilities holding about 1.3 million residents. Packaging is bought there as a line in the per-diem and priced per pack, not as a household subscription, which is why it is the part of this market that is already at scale.
And state Medicaid is the one place that pays explicitly. Washington State’s administrative code reimburses pharmacies for compliance packaging services — a filling fee plus reimbursement for the packaging device and container — for clients at risk of adverse drug therapy outcomes, defined as those with named chronic conditions taking two or more medications at three or more dosing intervals a day, or with a documented pattern of non-compliance. Read that rule closely. It does not pay for a device because a device is clever. It pays because the pack is auditable and the client is identifiable.
The quality route is real, and it is indirect
There is one more payer pathway, and it runs through a scoreboard rather than a benefit. Part D contracts are rated partly on three medication adherence measures: diabetes medications, hypertension (RAS antagonists) and cholesterol (statins). In the 2026 Star Ratings, the average measure score across MA-PD contracts was 3.1, 3.3 and 3.2; for stand-alone prescription drug plans it was 2.7, 2.6 and 2.7. The 2026 ratings drive 2027 quality bonus payments.
A plan that moves a population’s proportion of days covered across a cut point is moving revenue, not just quality. That makes managed dispensing a plausible plan purchase for the first time — but indirectly, as an instrument for a measure, and only where the vendor can show the measure moved. It is not a reimbursement code, and it does not solve the household’s problem.
What would change the market
Not a better device. The device has been good enough for a decade; the largest randomised trial of dose administration aids, at 26,635 patients, found an odds ratio of 1.03 for optimal adherence, which tells you the clinical endpoint is not where the value sits. What would change the market is adherence packaging and monitoring being written into managed care and PACE contracts as a covered service — a contracting decision that needs no statute, no coding decision and no new regulator, only an actuary willing to book the avoided readmission.
Until that happens, the growth we forecast is a substitution story rather than an adoption story. Two-thirds of it is more patient-years, and those patient-years come from channels where somebody else is paying: capitation, per-diems and state packaging rules. One-third is a richer bundle — because the pack, the delivery and the pharmacist’s review are worth more per patient than a reminder appliance ever was.
If you are underwriting a vendor in this category, ask for contracted patient-years by payer type. Units shipped measures marketing spend. Contracted patient-years measures whether anyone has agreed to pay.
Figures in this article are drawn from the Pheonix Research report Global Smart Pill Dispenser Market Report, Size, Share and Forecast 2026–2033. Sources include CMS 2026 Star Ratings publications, the Washington State Administrative Code, CMS PACE programme data, RXinsider’s 2025 long-term care pharmacy analysis, vendor published pricing and the peer-reviewed adherence literature.
Frequently Asked Questions
Why is smart pill dispenser penetration under two per cent?
Because the constraint is payment, not technology. In the United States automatic pill dispensers are not a Medicare benefit, and the adjacent paid benefits — a Part D medication therapy management review and state Medicaid compliance-packaging reimbursement — do not pay for a dispenser. Growth therefore depends on buyers who carry financial risk, such as PACE programmes, Medicaid agencies and long-term care operators.
Who pays for a smart pill dispenser today?
Households pay out of pocket. Hero publishes USD 39.99 a month on a prepaid annual plan, USD 44.99 with a twelve-month commitment and USD 59.99 with no commitment, which is USD 480 to USD 720 per patient-year before the cost of the medication itself.
Does Medicare pay for adherence in any form?
Because Part D contracts are rated partly on three medication adherence measures, and the 2026 ratings drive 2027 quality bonus payments. A plan that moves its members' proportion of days covered across a cut point is moving revenue, which makes managed dispensing a plausible plan purchase — indirectly, as an instrument for a quality measure.
What would actually unlock this market?
A better device would not do it. The change would come from adherence packaging and monitoring being written into managed care and PACE contracts as a covered service, which needs no new statute or coding decision — only a plan actuary willing to book the avoided readmission.
